300573 Stock Overview
Engages in the research and development, production, and sale of ophthalmic drug in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Shenyang Xingqi Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥52.16 |
| 52 Week High | CN¥152.79 |
| 52 Week Low | CN¥46.34 |
| Beta | 0.54 |
| 1 Month Change | -9.10% |
| 3 Month Change | 3.77% |
| 1 Year Change | -64.55% |
| 3 Year Change | 11.68% |
| 5 Year Change | 20.47% |
| Change since IPO | 1,826.34% |
Recent News & Updates
Recent updates
Here's Why We Think Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Might Deserve Your Attention Today
Mar 17
Pinning Down Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) P/E Is Difficult Right Now
Feb 25These 4 Measures Indicate That Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Is Using Debt Safely
Jan 05Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) P/E Is Still On The Mark Following 49% Share Price Bounce
Oct 23Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Stocks Pounded By 30% But Not Lagging Market On Growth Or Pricing
Sep 08With EPS Growth And More, Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Makes An Interesting Case
Aug 19What You Can Learn From Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) P/S After Its 27% Share Price Crash
Jul 24Does Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Have A Healthy Balance Sheet?
Jun 28Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Is Increasing Its Dividend To CN¥3.00
May 21After Leaping 31% Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Shares Are Not Flying Under The Radar
May 10We Ran A Stock Scan For Earnings Growth And Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Passed With Ease
May 07Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Looks Just Right With A 26% Price Jump
Mar 15Shareholder Returns
| 300573 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -6.4% | 2.7% | -0.01% |
| 1Y | -64.5% | 11.4% | 10.1% |
Return vs Industry: 300573 underperformed the CN Pharmaceuticals industry which returned 11.4% over the past year.
Return vs Market: 300573 underperformed the CN Market which returned 10.1% over the past year.
Price Volatility
| 300573 volatility | |
|---|---|
| 300573 Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in CN Market | 10.0% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 300573 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300573's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1977 | 2,426 | E. Gao | www.sinqi.com |
Shenyang Xingqi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of ophthalmic drug in the People’s Republic of China. The company develops ophthalmic anti-infective drugs, other ophthalmic drugs, nonsteroidal anti-inflammatory drugs for ophthalmology, mydriatic and ciliary muscle paralytic drugs, ophthalmic anti-inflammatory/anti-infective compound drugs, dry eye products, miotic and anti-glaucoma drugs, and other drugs.
Shenyang Xingqi Pharmaceutical Co.,Ltd. Fundamentals Summary
| 300573 fundamental statistics | |
|---|---|
| Market cap | CN¥12.80b |
| Earnings (TTM) | CN¥449.21m |
| Revenue (TTM) | CN¥2.13b |
Is 300573 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300573 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.13b |
| Cost of Revenue | CN¥447.31m |
| Gross Profit | CN¥1.68b |
| Other Expenses | CN¥1.23b |
| Earnings | CN¥449.21m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.83 |
| Gross Margin | 79.00% |
| Net Profit Margin | 21.09% |
| Debt/Equity Ratio | 10.3% |
How did 300573 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/01 10:57 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shenyang Xingqi Pharmaceutical Co.,Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tielin Chen | Topsperity Securities |
| Jing Chen | Topsperity Securities |